Eloxx Pharmaceuticals, Inc. stock is up 284.11% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 24 November’s closed higher than October.
Eloxx Pharmaceuticals, Inc. focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.